查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1573011

血浆衍生性商品市场：按产品类型、应用、最终用户、来源划分 - 2025-2030 年全球预测

Blood Plasma Derivatives Market by Product Type (Albumin, Coagulation Factors, Immunoglobulins), Application (Diagnostics, Research, Therapeutic Use), End User, Source - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年血浆衍生性商品市值为4.8324亿美元，预计2024年将达5.2383亿美元，复合年增长率为9.65%，2030年将达到9.2133亿美元。

血浆衍生物是指源自人类血浆的治疗产品，例如免疫球蛋白、凝血因子和白蛋白，用于治疗多种疾病。这些衍生物的需求源自于它们在治疗免疫力缺乏疾病、血友病、自体免疫疾病等方面的重要作用。最终用途范围主要包括医院、诊所和研究机构，此类疗法对于挽救生命的干预措施至关重要。该市场受到血浆分馏技术进步、政府改善医疗基础设施的倡议以及研究机构和製药公司之间合作加强等因素的显着影响。人口老化和慢性病盛行率上升将进一步加速市场成长。然而，严格的监管政策和高昂的生产成本带来了重大挑战。此外，对血浆捐赠过程的道德担忧和输血传播感染疾病的潜在风险正在阻碍市场扩张。然而，基因研究和生物技术的进步为开发更有效的重组血浆衍生产品提供了机会。专注于改善血浆采集流程和简化供应链可以缓解一些限制。合成生物学的创新可以为更永续和更道德的生产方法铺平道路，并减少对人类捐赠者的依赖。投资研发伙伴关係来开拓这些领域，确保生产精简且合规，并将我们的地理覆盖范围扩展到医疗保健支出激增的新兴市场。此外，加强患者和医疗保健提供者对血浆衍生产品益处的教育可能会提高市场接受度和使用率。总体而言，随着潜在的技术创新为低成本和道德上合理的替代方案铺平了道路，市场有望成长。

主要市场统计
基准年[2023] 4.8324 亿美元
预测年份 [2024] 52383万美元
预测年份 [2030] 9.2133亿美元
复合年增长率（%） 9.65%

市场动态：快速发展的血浆衍生性商品市场的关键市场洞察

供需的动态交互作用正在改变血浆衍生性商品市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 慢性病的流行推动了全球对血浆衍生物的需求
    • 增加对医疗基础设施和先进血浆采集技术的投资
    • 政府支持血浆衍生物研发的倡议和利多政策
    • 提高患者和医疗保健专业人员对血浆衍生疗法的认识和可及性
  • 市场限制因素
    • 用于衍生性商品製造的收集、储存和分配血浆的物流复杂性
    • 影响血浆衍生物供应链的道德问题与捐赠者招募挑战
  • 市场机会
    • 扩大血浆衍生疗法在肿瘤学和重症加护中的使用
    • 技术进步提高血浆衍生物生产效率
    • 政府在突发公共卫生事件期间促进血浆产品使用的努力
  • 市场挑战
    • 血浆采集和处理的高成本限制了市场扩张
    • 血浆衍生性商品市场中替代疗法和生物技术创新的竞争加剧

波特五力：驾驭血浆衍生性商品市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解血浆衍生性商品市场的外部影响

外部宏观环境因素对血浆衍生性商品市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解血浆衍生性商品市场的竞争格局

对血浆衍生性商品市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵血浆衍生性商品市场供应商的绩效评估

FPNV定位矩阵是评估血浆衍生性商品市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘血浆衍生性商品市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对血浆衍生性商品市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病的增加导致全球对血浆衍生物的需求增加
      • 增加对医疗基础设施和先进血浆采集技术的投资
      • 支持血浆分馏产品研发的政府措施和优惠政策
      • 患者和医疗保健专业人员对血浆衍生疗法的认识和可及性正在提高
    • 抑制因素
      • 用于衍生性商品製造的收集、储存和运输血浆的物流复杂性
      • 影响血浆衍生物供应链的道德问题与捐赠者招募挑战
    • 机会
      • 扩大血浆衍生疗法在肿瘤学和加护治疗中的使用
      • 提高血浆分馏产品生产效率的技术进步
      • 政府在突发公共卫生事件期间促进血浆产品使用的努力
    • 任务
      • 血浆采集和处理的高成本限制了市场扩张
      • 由于血浆分馏产品市场的替代疗法和生物技术创新，竞争日益激烈
  • 市场区隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 血浆衍生性商品市场：依产品类型

  • 白蛋白
  • 凝血因子
    • 因子IX
    • 因子VIII
    • 纤维蛋白原浓缩物
    • 凝血酶原复合物浓缩物 (PCC)
  • 免疫球蛋白
    • 静脉注射（IVIG）
    • 皮下注射 (SCIG)

第七章 血浆衍生性商品市场：依应用分类

  • 诊断
  • 调查
  • 治疗用途
    • 心臟病学
    • 血液肿瘤学
    • 免疫学
    • 感染疾病
    • 神经病学
    • 呼吸系统医疗设备
    • 创伤急救

第八章 血浆衍生性商品市场：依最终用户分类

  • 学术研究所
  • 血库
  • 诊所
  • 诊断实验室
  • 医院

第九章 血浆衍生性商品市场：依来源分类

  • 人类血浆
  • 非人类血浆

第十章美洲血浆衍生性商品市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太血浆衍生性商品市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲/中东/非洲血浆衍生性商品市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-1A1A064C008F

The Blood Plasma Derivatives Market was valued at USD 483.24 million in 2023, expected to reach USD 523.83 million in 2024, and is projected to grow at a CAGR of 9.65%, to USD 921.33 million by 2030.

Blood plasma derivatives refer to therapeutic products originating from human plasma, including immunoglobulins, clotting factors, albumin, and others, used to treat a variety of medical conditions. The necessity of these derivatives stems from their vital role in treating immunodeficiency disorders, hemophilia, and autoimmune diseases, among others, which are on the rise globally due to increased diagnosis and awareness. The end-use scope primarily encompasses hospitals, clinics, and research institutions, where such therapeutics are crucial for life-saving interventions. The market is significantly influenced by factors like technological advancements in plasma fractionation, government initiatives to improve healthcare infrastructure, and increased collaborations between research institutions and pharmaceutical companies. An aging population and higher prevalences of chronic diseases further amplify market growth. However, stringent regulatory policies and the high cost of production pose notable challenges. Furthermore, ethical concerns related to plasma donation processes and potential risks of transfusion-transmitted infections hinder market expansion. Nevertheless, advancements in genetic research and biotechnology present opportunities for development of more efficient and recombinant plasma-derived products. Focusing on improving plasma collection processes and enhancing supply chain efficiency can mitigate some limitations. Innovations in synthetic biology open channels for more sustainable and ethical production methodologies, possibly reducing dependence on human donors. Business growth can be achieved by investing in R&D partnerships to explore these areas, ensuring streamlined and compliant production, and by expanding geographical reach to emerging markets witnessing an upsurge in healthcare spending. Additionally, enhancing patient and healthcare provider education on the benefits of plasma-derived products could foster market acceptance and usage. Overall, the market is poised for growth with potential innovations paving the way for less costly and ethically sound alternatives.

KEY MARKET STATISTICS
Base Year [2023] USD 483.24 million
Estimated Year [2024] USD 523.83 million
Forecast Year [2030] USD 921.33 million
CAGR (%) 9.65%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Blood Plasma Derivatives Market

The Blood Plasma Derivatives Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of chronic diseases driving demand for blood plasma derivatives globally
    • Rising investments in healthcare infrastructure and advanced plasma collection technologies
    • Government initiatives and favorable policies supporting blood plasma derivative research and development
    • Growing awareness and accessibility of plasma-derived therapies among patients and healthcare providers
  • Market Restraints
    • Logistical complexities in the collection, storage, and distribution of blood plasma for derivatives production
    • Ethical concerns and donor recruitment challenges affecting the supply chain of blood plasma derivatives
  • Market Opportunities
    • Expanding use of plasma-derived therapies in oncology and critical care
    • Technological advancements improving production efficiency of plasma derivatives
    • Government initiatives promoting the use of plasma products in public health emergencies
  • Market Challenges
    • High cost of blood plasma collection and processing limiting market expansion
    • Increasing competition from alternative therapies and biotechnology innovations in the plasma derivatives market

Porter's Five Forces: A Strategic Tool for Navigating the Blood Plasma Derivatives Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Blood Plasma Derivatives Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Blood Plasma Derivatives Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Blood Plasma Derivatives Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Blood Plasma Derivatives Market

A detailed market share analysis in the Blood Plasma Derivatives Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Blood Plasma Derivatives Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Blood Plasma Derivatives Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Blood Plasma Derivatives Market

A strategic analysis of the Blood Plasma Derivatives Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Blood Plasma Derivatives Market, highlighting leading vendors and their innovative profiles. These include ADMA Biologics, ARTHREX GmbH, Bio Products Laboratory Ltd, Biotest AG, BPL Holdings, China Biologic Products Holdings, Inc., CSL Behring, Emergent BioSolutions, Grifols, Intas Pharmaceuticals, Kamada Ltd., Kedrion Biopharma, LFB Group, Octapharma, Prothya Biosolutions, RAAS Blood Products, Sanquin, Shanghai RAAS Blood Products Co., Ltd., Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Blood Plasma Derivatives Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Albumin, Coagulation Factors, and Immunoglobulins. The Coagulation Factors is further studied across Factor IX, Factor VIII, Fibrinogen Concentrate, and Prothrombin Complex Concentrate (PCC). The Immunoglobulins is further studied across Intravenous (IVIG) and Subcutaneous (SCIG).
  • Based on Application, market is studied across Diagnostics, Research, and Therapeutic Use. The Therapeutic Use is further studied across Cardiology, Hemato-oncology, Immunology, Infectious Diseases, Neurology, Pulmonology, and Trauma Emergencies.
  • Based on End User, market is studied across Academic & Research Institutes, Blood Banks, Clinics, Diagnostic Laboratories, and Hospitals.
  • Based on Source, market is studied across Human Plasma and Non-Human Plasma.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic diseases driving demand for blood plasma derivatives globally
      • 5.1.1.2. Rising investments in healthcare infrastructure and advanced plasma collection technologies
      • 5.1.1.3. Government initiatives and favorable policies supporting blood plasma derivative research and development
      • 5.1.1.4. Growing awareness and accessibility of plasma-derived therapies among patients and healthcare providers
    • 5.1.2. Restraints
      • 5.1.2.1. Logistical complexities in the collection, storage, and distribution of blood plasma for derivatives production
      • 5.1.2.2. Ethical concerns and donor recruitment challenges affecting the supply chain of blood plasma derivatives
    • 5.1.3. Opportunities
      • 5.1.3.1. Expanding use of plasma-derived therapies in oncology and critical care
      • 5.1.3.2. Technological advancements improving production efficiency of plasma derivatives
      • 5.1.3.3. Government initiatives promoting the use of plasma products in public health emergencies
    • 5.1.4. Challenges
      • 5.1.4.1. High cost of blood plasma collection and processing limiting market expansion
      • 5.1.4.2. Increasing competition from alternative therapies and biotechnology innovations in the plasma derivatives market
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Blood Plasma Derivatives Market, by Product Type

  • 6.1. Introduction
  • 6.2. Albumin
  • 6.3. Coagulation Factors
    • 6.3.1. Factor IX
    • 6.3.2. Factor VIII
    • 6.3.3. Fibrinogen Concentrate
    • 6.3.4. Prothrombin Complex Concentrate (PCC)
  • 6.4. Immunoglobulins
    • 6.4.1. Intravenous (IVIG)
    • 6.4.2. Subcutaneous (SCIG)

7. Blood Plasma Derivatives Market, by Application

  • 7.1. Introduction
  • 7.2. Diagnostics
  • 7.3. Research
  • 7.4. Therapeutic Use
    • 7.4.1. Cardiology
    • 7.4.2. Hemato-oncology
    • 7.4.3. Immunology
    • 7.4.4. Infectious Diseases
    • 7.4.5. Neurology
    • 7.4.6. Pulmonology
    • 7.4.7. Trauma Emergencies

8. Blood Plasma Derivatives Market, by End User

  • 8.1. Introduction
  • 8.2. Academic & Research Institutes
  • 8.3. Blood Banks
  • 8.4. Clinics
  • 8.5. Diagnostic Laboratories
  • 8.6. Hospitals

9. Blood Plasma Derivatives Market, by Source

  • 9.1. Introduction
  • 9.2. Human Plasma
  • 9.3. Non-Human Plasma

10. Americas Blood Plasma Derivatives Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Blood Plasma Derivatives Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Blood Plasma Derivatives Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. ADMA Biologics
  • 2. ARTHREX GmbH
  • 3. Bio Products Laboratory Ltd
  • 4. Biotest AG
  • 5. BPL Holdings
  • 6. China Biologic Products Holdings, Inc.
  • 7. CSL Behring
  • 8. Emergent BioSolutions
  • 9. Grifols
  • 10. Intas Pharmaceuticals
  • 11. Kamada Ltd.
  • 12. Kedrion Biopharma
  • 13. LFB Group
  • 14. Octapharma
  • 15. Prothya Biosolutions
  • 16. RAAS Blood Products
  • 17. Sanquin
  • 18. Shanghai RAAS Blood Products Co., Ltd.
  • 19. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • 20. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. BLOOD PLASMA DERIVATIVES MARKET RESEARCH PROCESS
  • FIGURE 2. BLOOD PLASMA DERIVATIVES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BLOOD PLASMA DERIVATIVES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BLOOD PLASMA DERIVATIVES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BLOOD PLASMA DERIVATIVES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BLOOD PLASMA DERIVATIVES MARKET DYNAMICS
  • TABLE 7. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR IX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR VIII, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FIBRINOGEN CONCENTRATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATE (PCC), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INTRAVENOUS (IVIG), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SUBCUTANEOUS (SCIG), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HEMATO-ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PULMONOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY TRAUMA EMERGENCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HUMAN PLASMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY NON-HUMAN PLASMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 102. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 104. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 109. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 111. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 116. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 118. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 123. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 125. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 130. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 132. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 137. PHILIPPINES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. PHILIPPINES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 139. PHILIPPINES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. PHILIPPINES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 144. SINGAPORE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. SINGAPORE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 146. SINGAPORE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. SINGAPORE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 151. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 153. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 154. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 158. TAIWAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. TAIWAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 160. TAIWAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. TAIWAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 165. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 167. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 172. VIETNAM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. VIETNAM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 174. VIETNAM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. VIETNAM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 187. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 189. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 194. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 196. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 201. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 202. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 203. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 204. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 208. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 210. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 211. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 215. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 216. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 217. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 218. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 222. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 224. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 225. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 229. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 231. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 232. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 236. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 238. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 239. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 243. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 244. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 245. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 246. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 250. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 251. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 252. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 253. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 257. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 258. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 259. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 260. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 264. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 266. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 267. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 271. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 272. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 273. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 274. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 278. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 279. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 280. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 281. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 285. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 286. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 287. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 288. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 292. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 293. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 294. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 295. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 299. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 300. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 301. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 302. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 306. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 307. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 308. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 309. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 313. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 314. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 315. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 316. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED KINGDOM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 325. UNITED KINGDOM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 326. UNITED KINGDOM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 327. UNITED KINGDOM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 328. UNITED KINGDOM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)

TABLE 3